Registration studies — when should patients be deemed ineligible for aggressive therapy?

Rachel J. Cook, Jennifer Gill, Vinay Prasad

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

The approval of therapeutic agents that are tested in patients deemed ineligible for intensive or aggressive therapy is increasingly popular. This approach enables comparisons of novel therapies with less-aggressive agents, as well as data from nonrandomized studies to be used for market authorization. Herein, we discuss three mechanisms that could be adopted to avoid the temptation of applying this strategy excessively.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
DOIs
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Registration studies — when should patients be deemed ineligible for aggressive therapy?'. Together they form a unique fingerprint.

  • Cite this